Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Gemcitabine + Nab-paclitaxel |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Gemcitabine | Gemzar | Difluorodeoxycytidine Hydrochlorothiazide|LY-188011 | Chemotherapy - Antimetabolite 14 | Gemzar (gemcitabine) is converted in cells to difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP), which act to inhibit ribonucleoside reductase and as a deoxynucleotide analog respectively, resulting in DNA strand termination and apoptosis (NCI Drug Dictionary). |
Nab-paclitaxel | Abraxane | ABI-007|Paclitaxel Protein-bound | Chemotherapy - Taxane 3 | Abraxane (nab-paclitaxel) is an albumin-stablized version of paclitaxel, which binds microtubules and prevents depolymerization, resulting in decreased cell motility and division (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
No data available in table |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02340117 | Phase II | SGT-53 Gemcitabine + Nab-paclitaxel | Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer | Active, not recruiting | USA | 0 |
NCT03816163 | Phase II | Gemcitabine + Nab-paclitaxel Gemcitabine + Nab-paclitaxel + Zolbetuximab | A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer | Active, not recruiting | USA | TUR | ITA | IRL | FRA | ESP | BRA | AUS | 5 |
NCT04390399 | Phase II | Fluorouracil + Irinotecan + Leucovorin Gemcitabine + Nab-paclitaxel Aldoxorubicin + Cyclophosphamide + Gemcitabine + Nab-paclitaxel + Nogapendekin alfa inbakicept + PD-L1.t-haNK cells Aldoxorubicin + Cyclophosphamide + Gemcitabine + Nab-paclitaxel + Nogapendekin alfa inbakicept | Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer | Active, not recruiting | USA | 0 |
NCT05042128 | Phase II | Gemcitabine + Nab-paclitaxel CEND-1 + Gemcitabine + Nab-paclitaxel | The ASCEND Study: Gemcitabine and Nab-Paclitaxel With CEND-1 or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma (ASCEND) | Active, not recruiting | NZL | AUS | 0 |
NCT05630183 | Phase II | Gemcitabine + Nab-paclitaxel Botensilimab + Gemcitabine + Nab-paclitaxel | A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer | Active, not recruiting | USA | 0 |
NCT06119217 | Phase II | Gemcitabine + Nab-paclitaxel + TTX-030 Gemcitabine + Nab-paclitaxel Budigalimab + Gemcitabine + Nab-paclitaxel + TTX-030 | Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients | Active, not recruiting | USA | ITA | FRA | ESP | AUS | 2 |
NCT01488552 | Phase Ib/II | Oxaliplatin Fluorouracil + Irinotecan + Leucovorin Gemcitabine + Nab-paclitaxel Metformin | Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer | Completed | USA | 0 |
NCT01803282 | Phase I | Andecaliximab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Carboplatin + Pemetrexed Disodium Fluorouracil + Irinotecan + Leucovorin Gemcitabine + Nab-paclitaxel Carboplatin + Paclitaxel Paclitaxel Bevacizumab | Safety and Tolerability Study in Solid Tumors | Completed | USA | 0 |
NCT02077881 | Phase Ib/II | Indoximod Gemcitabine + Nab-paclitaxel | Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer | Completed | USA | 0 |
NCT02436668 | Phase II | Gemcitabine + Nab-paclitaxel Ibrutinib | Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma | Completed | USA | ITA | GBR | FRA | ESP | DEU | BEL | 1 |
NCT02574663 | Phase I | Gemcitabine + Nab-paclitaxel Bevacizumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Umbralisib | TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors | Completed | USA | 0 |
NCT02879318 | Phase II | Gemcitabine + Nab-paclitaxel Durvalumab + Tremelimumab | Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Pancreatic Adenocarcinoma | Completed | CAN | 0 |
NCT02993731 | Phase III | Gemcitabine + Nab-paclitaxel + Napabucasin Gemcitabine + Nab-paclitaxel | A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma (CanStem111P) | Completed | USA | POL | NLD | ITA | FRA | ESP | DEU | CZE | CAN | BEL | AUT | AUS | 8 |
NCT03086369 | Phase Ib/II | Gemcitabine + Nab-paclitaxel + Olaratumab Gemcitabine + Nab-paclitaxel | A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer | Completed | USA | ESP | DEU | 0 |
NCT03336216 | Phase II | Cabiralizumab + Gemcitabine + Nab-paclitaxel + Nivolumab Cabiralizumab + Nivolumab Fluorouracil + Irinotecan + Leucovorin Gemcitabine + Nab-paclitaxel Cabiralizumab + Fluorouracil + Irinotecan + Leucovorin + Nivolumab | A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer | Completed | USA | ITA | GBR | ESP | DNK | DEU | CHE | CAN | 3 |
NCT03496662 | Phase Ib/II | Nivolumab BMS-813160 + Gemcitabine + Nab-paclitaxel Gemcitabine + Nab-paclitaxel BMS-813160 + Gemcitabine + Nab-paclitaxel + Nivolumab | BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) | Completed | USA | 0 |
NCT03507491 | Phase I | Gemcitabine + Nab-paclitaxel | Nab-paclitaxel in Combination With Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors | Completed | USA | 0 |
NCT03665441 | Phase III | Eryaspase + Gemcitabine + Nab-paclitaxel Eryaspase + Fluorouracil + Irinotecan + Leucovorin Fluorouracil + Irinotecan + Leucovorin Gemcitabine + Nab-paclitaxel | Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC (Trybeca-1) | Completed | USA | GBR | FRA | 0 |
NCT04229004 | Phase III | Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Gemcitabine + Nab-paclitaxel | A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer | Completed | USA | 0 |
NCT04935359 | Phase III | Gemcitabine + Nab-paclitaxel + NIS793 Gemcitabine + Nab-paclitaxel | Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2 | Completed | USA | TUR | SWE | SVK | NOR | NLD | ITA | ISR | HUN | GRC | GBR | FRA | FIN | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUS | 6 |
NCT05673811 | Phase II | Gemcitabine + Nab-paclitaxel + VCN-01 Gemcitabine + Nab-paclitaxel | Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer (VIRAGE) | Completed | USA | ESP | 0 |
NCT05254171 | Phase II | Gemcitabine + Nab-paclitaxel + SBP-101 Gemcitabine + Nab-paclitaxel | Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer (ASPIRE) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | BEL | AUT | AUS | 1 |
NCT05821556 | Phase II | Capecitabine + Cisplatin + Gemcitabine + Nab-paclitaxel + Simvastatin + Valproic acid Gemcitabine + Nab-paclitaxel + Simvastatin + Valproic acid Gemcitabine + Nab-paclitaxel Capecitabine + Cisplatin + Gemcitabine + Nab-paclitaxel | Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients | Recruiting | ITA | ESP | 0 |
NCT06333314 | Phase II | Dostarlimab-gxly Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Doxorubicin Gemcitabine Gemcitabine + Nab-paclitaxel Doxorubicin + Trabectedin Fluorouracil + Leucovorin + Oxaliplatin Cisplatin + Etoposide Cisplatin + Gemcitabine Cisplatin + Doxorubicin + Etoposide Capecitabine + Oxaliplatin Doxorubicin + Ifosfamide Carboplatin + Etoposide Carboplatin + Paclitaxel Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin Mitotane | Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI (Pan-MSI-ACSE) | Recruiting | FRA | 0 |
NCT06608927 | Phase III | Gemcitabine + Nab-paclitaxel AB680 + Gemcitabine + Nab-paclitaxel | Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PRISM-1) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 2 |
NCT06625320 | Phase III | Fluorouracil + Leucovorin + Liposomal irinotecan Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Gemcitabine + Nab-paclitaxel Daraxonrasib | Phase 3 Study of RMC-6236 in Patients with Previously Treated Metastatic Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RASolute 302) | Recruiting | USA | ITA | FRA | ESP | 2 |
NCT01621243 | Phase Ib/II | Gemcitabine + Nab-paclitaxel Necuparanib | M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer | Terminated | USA | CAN | 0 |
NCT01804530 | Phase I | PLX7486 Gemcitabine + Nab-paclitaxel | Phase 1 Study of PLX7486 as Single Agent and With Gemcitabine Plus Nab-Paclitaxel in Patients With Advanced Solid Tumors | Terminated | USA | 0 |
NCT01921751 | Phase II | Gemcitabine + Nab-paclitaxel Capecitabine | High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery | Terminated | USA | 0 |
NCT02101021 | Phase II | Gemcitabine + Nab-paclitaxel Momelotinib | Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma | Terminated | USA | 0 |
NCT02109445 | Phase II | Gemcitabine + Nab-paclitaxel Nirogacestat | Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies | Terminated | USA | 0 |
NCT02570711 | Phase II | Acalabrutinib Gemcitabine + Nab-paclitaxel | Study of Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Previously Untreated Metastatic Pancreatic Cancer | Terminated | USA | 0 |
NCT04390763 | Phase II | Gemcitabine + Nab-paclitaxel Gemcitabine + Nab-paclitaxel + NIS793 + Spartalizumab Gemcitabine + Nab-paclitaxel + NIS793 | Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) (daNIS-1) | Terminated | USA | ITA | GBR | FRA | FIN | ESP | DEU | CZE | CHE | BEL | AUT | AUS | 2 |
NCT04983407 | Phase Ib/II | AVB-S6-500 + Gemcitabine + Nab-paclitaxel Gemcitabine + Nab-paclitaxel | Safety and Efficacy Study of AVB-S6-500 in Patients With Advanced Pancreatic Adenocarcinoma | Terminated | USA | 0 |
NCT01676259 | Phase II | Gemcitabine + Nab-paclitaxel + siG12D-LODER Gemcitabine + Nab-paclitaxel | A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer (PROTACT) | Unknown status | USA | ISR | 0 |
NCT04257448 | Phase Ib/II | Gemcitabine + Nab-paclitaxel + Romidepsin Azacitidine + Gemcitabine + Nab-paclitaxel Azacitidine + Gemcitabine + Nab-paclitaxel + Romidepsin Gemcitabine + Nab-paclitaxel Durvalumab + Lenalidomide | Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer (SEPION) | Unknown status | DEU | 0 |
NCT03563144 | Phase II | Gemcitabine Gemcitabine + Nab-paclitaxel Aldoxorubicin + Avelumab + Bevacizumab + Capecitabine + Cyclophosphamide + ETBX-011 + ETBX-021 + ETBX-051 + ETBX-061 + Fluorouracil + Gemcitabine + GI-4000 + GI-6207 + GI-6301 + haNK cells + Leucovorin + Nab-paclitaxel + Nogapendekin alfa inbakicept + Oxaliplatin | QUILT-3.088: NANT Pancreatic Cancer Vaccine | Withdrawn | USA | 0 |
NCT06592664 | Phase Ib/II | Gemcitabine + Nab-paclitaxel CEND-1 + Gemcitabine + Nab-paclitaxel | LSTA1 Phase 1b/2a Continuous Infusion Trial in mPDAC (FORTIFIDE) | Withdrawn | 0 |
CKB CORE allows for only a limited number of monthly page views for un-registered users. However, registration is free and allows for unlimited browsing of the CKB CORE content.
You have reached the monthly page view limit. For continued free access to CKB CORE, please register below: